

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 50

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in *Cumulative List No. 10, 2002* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES : Liste 50

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45) dans la *Liste récapitulative No. 10, 2002* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS : Lista 50

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–85) y Recomendadas (1–45) se encuentran reunidas en *Cumulative List No. 10, 2002* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada

acidum arundicum

arundic acid

(2*R*)-2-propyloctanoic acid


acide arundique

(-)-acide (2*R*)-2-propyloctanoïque

ácido arúndico

ácido (2*R*)-2-propiloctanoico

$C_{11}H_{22}O_2$



acidum salcaproxicum

salcaproxic acid

8-(2-hydroxybenzamido)octanoic acid


acide salcaproziq

acide 8-[(2-hydroxybenzoyl)amino]octanoïque

ácido salcaprózico

ácido 8-(2-hidroxibenzamido)octanoico

$C_{15}H_{21}NO_4$



alvocidibum

alvocidib



(-)-2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3*R**,4*S**)-3-hydroxy-1-methyl-4-piperidyl]-4*H*-chromen-4-one

alvocidib

(-)-2-(2-chlorophényl)-5,7-dihydroxy-8-[(3*R**,4*S**)-3-hydroxy-1-méthylpipéridin-4-yl]-4*H*-1-benzopyran-4-one

alvocidib

(-)-2-(2-clorofenil)-5,7-dihidroxi-8-[(3*R**,4*S**)-3-hidroxi-1-metilpiperidin-4-il]-4*H*-cromen-4-ona



anatibantum
anatibant



(2S)-N-[3-(4-carbamimidoylbenzamido)propyl]-1-[2,4-dichloro-3-[(2,4-dimethyl-8-quinolyloxy)methyl]phenylsulfonyl]pyrrolidine-2-carboxamide

anatibant

(2S)-N-[3-[(4-carbamimidoylbenzoyl)amino]propyl]-1-[[2,4-dichloro-3-[(2,4-diméthylquinoléin-8-yl)oxy]méthyl]phényl]sulfonyl]pyrrolidine-2-carboxamide

anatibant

(2S)-N-[3-[(4-carbamimidoylbenzamido)propyl]-1-[2,4-dichloro-3-[(2,4-diméthylquinoléin-8-iloxi]metil]fenil]sulfonyl]pirrolidina-2-carboxamida



ardenerminum
ardenermin



B-lymphocyte stimulator-(134-285)-peptide

ardénermine

peptide-(134-285)-stimulateur du lymphocyte-B humain

ardenermina

péptido-(134-285)-estimulante del linfocito-B humano



arimoclomolum


arimoclomol

N-[(2*R*)-2-hydroxy-3-(1-piperidyl)propoxy]pyridine-3-carboximidoyl chloride, 1-oxide

arimoclomol

1-oxyde du chlorure de *N*-[(2*R*)-2-hydroxy-3-(pipéridin-1-yl)propoxy]pyridin-3-carboximidoyle

arimoclomol

1-óxido del cloruro de (Z)-*N*-[(2*R*)-2-hidroxi-3-(1-piperidil)propoxi]piridina-3-carboximidoilo $C_{14}H_{20}ClN_3O_3$ **aselizumabum**

aselizumab

immunoglobulin G4, anti-(L-selectin) (human-mouse monoclonal HuDreg-55 heavy chain), disulfide with human-mouse monoclonal HuDreg-55 light chain, dimer

asélizumab

immunoglobuline G4, anti-(sélectine L) (chaîne lourde de l'anticorps monoclonal de souris HuDreg-55 humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris HuDreg-55 humanisé

aselizumab

inmunoglobulina G4, anti-(selectina L) (cadena pesada del anticuerpo monoclonal humanizado de ratón HuDreg-55), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón HuDreg-55

asoprisnili ecamas


asoprisnil ecamate

11β-[4-[(*E*)-(ethylcarbamoyloxyimino)methyl]phenyl]-17β-methoxy-17α-(methoxymethyl)estra-4,9-dien-3-one

écamate d'asoprisnil

11β-[4-[(*E*)-[(éthylcarbamoyl)oxy]imino]méthyl]phényl]-17β-méthoxy-17-(méthoxyméthyl)estra-4,9-dién-3-one

ecamato de asoprisnilo

11β-[4-[(*E*)-[(etilcarbamoil)oxi]imino]metil]fenil]-17β-metoxi-17α-(metoximetil)estra-4,9-dien-3-ona $C_{31}H_{40}N_2O_5$ 

ataciguatum


ataciguat

5-chloro-2-[(5-chloro-2-thienyl)sulfonylamino]-*N*-[4-(morpholin-4-ylsulfonyl)phenyl]benzamide

ataciguat

5-chloro-2-[[5-chlorothiophén-2-yl)sulfonyl]amino]-*N*-[4-(morpholin-4-ylsulfonyl)phényl]benzamide

ataciguat

5-cloro-2-[[5-cloro-2-tienil)sulfonilamino]-*N*-[4-(morfolin-4-ilsulfonil)fenil]benzamida $C_{21}H_{19}Cl_2N_3O_6S_3$ **atazanavirum**


atazanavir

dimethyl (3*S*,8*S*,9*S*,12*S*)-9-benzyl-3,12-di-*tert*-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate

atazanavir

(3*S*,8*S*,9*S*,12*S*)-9-benzyl-3,12-bis(1,1-diméthyléthyl)-8-hydroxy-4,11-dioxo-6-[4-(pyridin-2-yl)benzyl]-2,5,6,10,13-pentaazatétradécanedioate de diméthyle

atazanavir

(3*S*,8*S*,9*S*,12*S*)-9-bencil-3,12-di-*tert*-butil-8-hidroxi-4,11-dioxo-6-[4-(2-piridil)benzil]-2,5,6,10,13-pentaazatetradecanodioate de dimetilo $C_{38}H_{52}N_6O_7$ **barixibatum**

barixibat



11-(D-gluconamido)-*N*-{2-[(1*S*,2*R*,3*S*)-3-hydroxy-3-phenyl-2-(2-pyridyl)-1-(2-pyridylamino)propyl]phenyl}undecanamide

barixibat

11-(D-gluconylamino)-*N*-[2-[(1*S*,2*R*,3*S*)-3-hydroxy-3-phényl-2-(pyridin-2-yl)-1-(pyridin-2-ylamino)propyl]phényl]undécanamide

barixibat

{*N*-[2-[(1*S*,2*R*,3*S*)-3-fenil-3-hidroxi-2-(piridin-2-il)-1-(piridin-2-ilamino)propil]fenil]-11-(D-gluconamido)}undecanamida



barusibanum
barusiban


$C^{4,6}, S^1$ -cyclo[*N*-(3-sulfanylpropanoyl)-D-tryptophyl-L-isoleucyl-L-alloisoleucyl-L-asparaginyl-L-2-aminobutanoyl-*N*-methyl-L-ornithinol]

barusiban

(4*S*,7*S*,10*S*,13*S*,16*R*)-*N*-[(1*S*)-4-amino-1-(hydroxyméthyl)butyl]-7-(2-amino-2-oxoéthyl)-16-(1*H*-indol-3-ylméthyl)-*N*-méthyl-10-[(1*R*)-1-méthylpropyl]-13-[(1*S*)-1-méthylpropyl]-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

barusibán

$C^{4,6}, S^1$ -ciclo[*N*-(3-sulfanilpropanoil)-D-triptofil-L-isoleucil-L-alloisoleucil-L-asparaginil-L-2-aminobutanoil-*N*-metil-L-ornitinol]



bertilimumabum
bertilimumab

immunoglobulin G4, anti-(human eotaxin 1) (human monoclonal CAT-213 γ4-chain), disulfide with human monoclonal CAT-213 κ-chain, dimer

bertilimumab

immunoglobuline G4, anti-(éotaxine 1 humaine) (chaîne γ4 de l'anticorps monoclonal humain CAT-213), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal humain CAT-213

bertilimumab

inmunoglobulina G4, anti-(eotaxina 1 humana) (cadena γ4 del anticuerpo monoclonal humano CAT-213), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humano CAT-213

bortezomibum


bortezomib

{(1*R*)-3-methyl-1-[(2*S*)-3-phenyl-2-(pyrazin-2-carboxamido)=propanamido]butyl}boronic acid

bortézomib

acide [(1*R*)-3-méthyl-1-[[[(2*S*)-3-phényl-2-[(pyrazinylcarbonyl)amino]=propanoyl]amino]butyl]boronique

bortezomib

ácido {(1*R*)-3-metil-1-[(2*S*)-3-fenil-2(pirazin-2-carboxamido)=propanamido]butil}borónico $C_{19}H_{25}BN_4O_4$ **cinacalcetum**


cinacalcet

N-[(1*R*)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine

cinacalcet

N-[(1*R*)-1-(naphtalén-1-yl)éthyl]-3-[3-(trifluorométhyl)phényl]propan-1-amine

cinacalcet

N-[(1*R*)-1-(1-naftil)etil]-3-[3-(trifluorometil)fenil]propan-1-amina $C_{22}H_{22}F_3N$ **darunavirum**

darunavir



(3*R*,3*aS*,6*aR*)-hexahydrofuro[2,3-*b*]furan-3-yl *N*-[(1*S*,2*R*)-1-benzyl-2-hydroxy-3-(*N*¹-isobutylsulfanilamido)propyl]carbamate

darunavir

[(1*S*,2*R*)-3-[[[(4-aminophényl)sulfonyl](2-méthylpropyl)amino]-1-benzyl-2-hydroxypropyl]carbamate de (3*R*,3*aS*,6*aR*)-hexahydrofuro[2,3-*b*]furan-3-yle

darunavir



N-[(1*S*,2*R*)-1-bencil-2-hidroxi-3-(*N*-isobutilsulfanilamido)propil]=carbamato de (3*R*,3*aS*,6*aR*)-hexahidrofuro[2,3-*b*]furan-3-ilo

**dexmethylphenidatum**

dexmethylphenidate

dexméthylphénidate



dexmetilfenidato

methyl (2*R*)-phenyl[(2*R*)-2-piperidyl]acetate(2*R*)-phényl[(2*R*)-pipéridin-2-yl]acétate de méthyle(2*R*)-fenil[(2*R*)-2-piperidiil]acetato de metilo**disufentonum natricum**

disufenton sodium

disufenton sodique

disufentón de sodio



disodium 4-(*tert*-butyliminomethyl)benzene-1,3-disulfonate *N*-oxide*N*-oxyde de 4-[[[1,1-diméthyléthyl]imino]méthyl]benzène-1,3-disulfonate de disodium*N*-óxido de 4-terc-butyliminometil]benceno-1,3-disulfonato de disodio**dofequidarum**

dofequidar

doféquidar

dofequidar

1-(diphenylacetyl)-4-[(2*RS*)-2-hydroxy-3-(5-quinolyloxy)propyl]piperazine1-(diphénylacétyl)-4-[(2*RS*)-2-hydroxy-3-(quinoléin-5-yloxy)propyl]pipérazine1-(difenilacetil)-4-[(2*RS*)-2-hidroxi-3-(quinolein-5-iloxi)propil]piperazina



doramapimodum
doramapimod



1-[3-*tert*-butyl-1-(4-methylphenyl)-1*H*-pyrazol-5-yl]-
3-[4-(2-morpholinoethoxy)-1-naphthyl]urea

doramapimod

1-[3-(1,1-diméthyléthyl)-1-(4-méthylphényl)-1*H*-pyrazol-5-yl]-
3-[4-[2-(morpholin-4-yl)éthoxy]naphtalén-1-yl]urée

doramapimod

1-[3-*terc*-butil-1-(4-metilfenil)-1*H*-pirazol-5-il]-3-[4-(2-morfolinoetoxi)-
1-naftil]urea



etiprednoli dicloacetatas
etiprednol dicloacetate



ethyl 17α-(dichloroacetoxy)-11β-hydroxy-3-oxoandrosta-1,4-diene-
17β-carboxylate

dicloacétate d'étiprednol

17-[(dichloroacétyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diène-
17β-carboxylate d'éthyle

dicloroacetato de etiprednol

17-[(dicloroacetil)oxi]-11β-hidroxi-3-oxoandrosta-1,4-dieno-
17β-carboxilato de etilo



etravirinum

etravirine


4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yloxy]-3,5-dimethylbenzonitrile

étravirine

4-[[6-amino-5-bromo-2-[(4-cyanophényl)amino]pyrimidin-4-yl]oxy]-3,5-diméthylbenzonitrile

etravirina

4-[6-amino-5-bromo-2-(4-cianoanilino)pirimidin-4-iloxi]-3,5-dimetilbenzonitrilo

 $C_{20}H_{15}BrN_6O$ **etriciguatum**


etriciguat

2-[1-(2-fluorobenzyl)-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl]-5-(4-pyridyl)pyrimidin-4-amine

étriciguat

2-[1-(2-fluorobenzyl)-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl]-5-(pyridin-4-yl)pyrimidin-4-amine

etriciguat

2-[1-(2-fluorobencil)-1*H*-pirazolo[3,4-*b*]piridin-3-il]-5-(4-piridil)pirimidin-4-amina $C_{22}H_{16}FN_7$ **fipamezolum**


fipamezole

4-[(2*RS*)-2-ethyl-5-fluoroindan-2-yl]-1*H*-imidazole

fipamézole

4-[(2*RS*)-2-éthyl-5-fluoro-2,3-dihydro-1*H*-indén-2-yl]-1*H*-imidazole

fipamezol

4-[(2*RS*)-2-etil-5-fluoroindan-2-il]-1*H*-imidazol $C_{14}H_{15}FN_2$ 

gemcabenum

gemcabene


2,2,2',2'-tetramethyl-6,6'-oxydihexanoic acid

gemcabène

acide 6,6'-oxybis(2,2-diméthylhexanoïque)

gemcabeno

ácido 2,2,2',2'-tetrametil-6,6'-dihexanoico

**ibrolipimum**

ibrolipim


diethyl {4-[(4-bromo-2-cyanophenyl)carbamoyl]benzyl}phosphonate

ibrolipim

[4-[(4-bromo-2-cyanophényl)carbamoyl]benzyl]phosphonate de diéthyle

ibrolipim

[4-[(4-bromo-2-cianofenil)carbamoil]bencil]fosfonato de dietilo

**iclaprimum**



iclaprim

5-[(2*RS*)-2-cyclopropyl-7,8-dimethoxy-2*H*-chromen-5-ylmethyl]pyrimidine-2,4-diamine

iclaprime

5-[[[(2*RS*)-2-cyclopropyl-7,8-diméthoxy-2*H*-1-benzopyran-5-yl]méthyl]pyrimidine-2,4-diamine

iclaprim

5-[(2*RS*)-2-ciclopropil-7,8-dimetoxi-2*H*-cromen-5-ilmetil]pirimidina-2,4-diamina

iosimenolum


iosimenol

5,5'-[propanedioylbis[(2,3-dihydroxypropyl)imino]bis[*N*-(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide]

iosiménol

5,5'-[propanedioylbis[(2,3-dihydroxypropyl)imino]bis[*N*-(2,3-dihydroxypropyl)-2,4,6-triiodobenzène-1,3-dicarboxamide]

iosimenol

5,5'-[propanodioilbis[(2,3-dihidroxiopropil)imino]bis[*N*-(2,3-dihidroxiopropil)-2,4,6-triiodobenceno-1,3-dicarboxamida] $C_{31}H_{36}I_6N_6O_{14}$ **latidectinum**

latidectin

mixture of components A₄ and A₃component A₄

(2a¹S,2aE,4E,5'S,6S,6'R,7R,8E,11R,13R,15S,17aR,20R,20aR)-6'-ethyl-2a¹,20-dihydroxy-5',6,8,19-tetramethyl-17-oxo-2a¹,3',4',5',6,6',7,10,11,14,15,17a,20,20a-tetradecahydro-2H,13H,17H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 1-[4-(methoxyacetamido)phenyl]cyclopentanecarboxylate

component A₃

(2a¹S,2aE,4E,5'S,6S,6'R,7R,8E,11R,13R,15S,17aR,20R,20aR)-2a¹,20-dihydroxy-5',6,6',8,19-pentamethyl-17-oxo-2a¹,3',4',5',6,6',7,10,11,14,15,17a,20,20a-tetradecahydro-2H,13H,17H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-[2H]pyran]-7-yl 1-[4-(methoxyacetamido)phenyl]cyclopentanecarboxylate

latidectine

mélange des composés A₄ et A₃composé A₄

1-[4-[(méthoxyacétyl)amino]phényl]cyclopentanecarboxylate de (2aE,4E,5'S,6S,6'R,7R,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-éthyl-20,20b-dihydroxy-5',6,8,19-tétraméthyl-17-oxo-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tétradécahydrospiro[11,15-méthano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadécine-13,2'-[2H]pyran]-7-yle

composé A₃

1-[4-[(méthoxyacétyl)amino]phényl]cyclopentanecarboxylate de (2aE,4E,5'S,6S,6'R,7R,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,6',8,19-tétraméthyl-17-oxo-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tétradécahydrospiro[11,15-méthano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadécine-13,2'-[2H]pyran]-7-yle


latidectina

mezcla de los componentes A₄ y A₃componente A₄

1-[4-[(metoxiacetamido)fenil]ciclopentanocarboxilato de
(2a¹S,2aE,4E,5'S,6S,6'R,7R,8E,11R,13R,15S,17aR,20R,20aR), -
6'-etil-2a¹,20-dihidroxi-5',6,8,19-tetrametil-17-oxo-
2a¹,3',4',5',6,6',7,10,11,14,15,17a,20,20a, -tetradecahidro-
2H,13H,17H-spiro[11,15-metanofuro[4,3,2-
pq][2,6]benzodioxaciclooctadecino-13,2'-[2H]piran]-7-ilo

componente A₃

1-[4-[(metoxiacetamido)fenil]ciclopentanocarboxilato de
(2a¹S,2aE,4E,5'S,6S,6'R,7R,8E,11R,13R,15S,17aR,20R,20aR), -
2a¹,20,-dihidroxi-5',6,6',8,19-pentametil-17-oxo-
2a¹,3',4',5',6,6',7,10,11,14,15,17a,20,20a, -tetradecahidro-
2H,13H,17H-spiro[11,15-metano-furo[4,3,2-
pq][2,6]benzodioxaciclooctadecino-13,2'-[2H]piran]-7-ilo

C₄₆H₆₁NO₁₁ (component A₃)C₄₇H₆₃NO₁₁ (component A₄)

lurasidonum

lurasidone


(3aR,4S,7R,7aS)-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl]hexahydro-4,7-methano-2H-isoindole-1,3-dione

lurasidone

(3aR,4S,7R,7aS)-2-[[[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]méthyl]cyclohexyl]méthyl]hexahydro-4,7-méthano-2H-isoindole-1,3-dione

lurasidona

3aR,4S,7R,7aS)-2-[[[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]méthyl]cyclohexyl]méthyl]hexahydro-4,7-méthano-2H-isoindole-1,3-dione

C₂₆H₃₆N₄O₂S

mantabegronum


mantabegron

(2*RS*)-1-(adamantan-1-ylamino)-3-phenoxypropan-2-ol

mantabégron

(2*RS*)-1-phénoxy-3-(tricyclo[3.3.1.1^{3,7}]-déc-1-ylamino)propan-2-ol

mantabegrón

(2*RS*)-1-fenoxi-3-(tricyclo[3.3.1.1^{3,7}]-dec-1-ilamino)propan-2-olC₁₉H₂₇NO₂**matuzumabum**

matuzumab

immunoglobulin G1, anti-(human epidermal growth factor receptor)
(humanized MAb 425 γ1 chain), disulfide with humanized MAb 425
κ-chain, dimer

matuzumab

immunoglobuline G1, anti-(récepteur du facteur de croissance
humain de l'épiderme) (chaîne γ1 de l'anticorps monoclonal de
souris 425 humanisé), dimère du disulfure avec la chaîne κ de
l'anticorps monoclonal de souris 425 humanisé

matuzumab

immunoglobulina G1, anti-(receptor humano del factor de crecimiento
de la epidermis) (cadena γ1 del anticuerpo monoclonal humanizado
de ratón 425), dímero del disulfuro con la cadena κ del anticuerpo
monoclonal humanizado de ratón 425**meclinertantum**


meclinertant

2-[[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1*H*-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.1^{3,7}]decane-2-carboxylic acid

méclinertant

acide 2-[[[1-(7-chloroquinoléin-4-yl)-5-(2,6-diméthoxyphényl)-1*H*-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.1^{3,7}]décano-2-carboxylique

meclinertant

ácido 2-[[[1-(7-cloroquinolin-4-il)-5-(2,6-dimetoxifenil)-1*H*-pirazol-3-il]carbonil]amino]tríciclo[3.3.1.1^{3,7}]decano-2-carboxílicoC₃₂H₃₁ClN₄O₅

mitratapidum

mitratapide


2-[(2*R*)-butan-2-yl]-4-(4-{4-[4-((2*S*,4*R*)-2-(4-chlorophenyl)-2-[(4-methyl-4*H*-1,2,4-triazol-3-ylsulfanyl)methyl]-1,3-dioxolan-4-yl)methoxy]phenyl}piperazin-1-yl)phenyl)-2,4-dihydro-3*H*-1,2,4-triazol-3-one

mitratapide

4-[4-[4-[4-[(2*S*,4*R*)-2-(4-chlorophényl)-2-[(4-méthyl-4*H*-1,2,4-triazol-3-yl)sulfanyl]méthyl]-1,3-dioxolan-4-yl]méthoxy]phényl]pipérazin-1-yl]phényl]-2-[(1*R*)-1-méthylpropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one

mitratapida

2-[(2*R*)-butan-2-il]-4-(4-{4-[4-({2-(4-clorofenil)-2-[(2*S*,4*R*)-(4-metil-4*H*-1,2,4-triazol-3-ilsulfanil)metil]-1,3-ioxolan-4-il}metoxi)=fenil]piperazin-1-il}fenil)-2,4-dihidro-3*H*-1,2,4-triazol-3-ona

C₃₆H₄₁ClN₈O₄S**oxeglitazarum**

oxeglitazar


(2*E*,4*E*)-5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid

oxéglitazar

acide (2*E*,4*E*)-5-(7-méthoxy-3,3-diméthyl-2,3-dihydro-1-benzoxépin-5-yl)-3-méthylpenta-2,4-diénoïque

oxeglitazar

ácido (2*E*,4*E*)-3-metil-5-(3,3-dimetil-7-metoxi-2,3-dihidro-1-benzoxepin-5-il)penta-2,4-dienoico

C₁₉H₂₂O₄**posizolidum**

posizolid



(5*R*)-3-(4-{1-[(2*S*)-2,3-dihydroxypropanoyl]-1,2,3,6-tetrahydro-4-pyridyl}-3,5-difluorophenyl)-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one

posizolid

(5*R*)-3-[4-[1-[(2*S*)-2,3-dihydroxypropanoyl]-1,2,3,6-tétrahydropyridin-4-yl]-3,5-difluorophényl]-5-[(isoxazol-3-yloxy)méthyl]oxazolidin-2-one

posizolid

(5*R*)-3-(4-{1-[(2*S*)-2,3-dihidroxiopropanoil]-1,2,3,6-tetrahidro-4-piridil}-3,5-difluorofenil)-5-[(isoxazol-3-illoxi)metil]oxazolidin-2-ona

**rafabegronum**



rafabegron

(3-[(2*R*)-2-[(2*R*)-2-(3-chlorophenyl)-2-hydroxyethylamino]propyl]-1*H*-indol-7-yloxy)acetic acid

rafabégron

acide [[3-[(2*R*)-2-[(2*R*)-2-(3-chlorophényl)-2-hydroxyéthyl]=amino]propyl]-1*H*-indol-7-yl]oxy]acétique

rafabegrón

ácido (3-[(2*R*)-2-[(2*R*)-2-(3-clorofenil)-2-hidroxitilamino]propil]-1*H*-indol-7-iloxi)acético**rupintrivirum**



rupintrivir

ethyl (2*E*,4*S*)-4-[(2*R*,5*S*)-2-(4-fluorobenzyl)-6-methyl-5-(5-methyl-1,2-oxazol-3-carboxamido)-4-oxoheptanamido]-5-[(3*S*)-2-oxopyrrolidin-3-yl]pent-2-enoate

rupintrivir

(2*E*,4*S*)-4-[[[(2*R*,5*S*)-2-(4-fluorobenzyl)-6-méthyl-5-[[[(5-méthylisoxazol-3-yl)carbonyl]amino]-4-oxoheptanoyl]amino]-5-[(3*S*)-2-oxopyrrolidin-3-yl]pent-2-énoate d'éthyle

rupintrivir

(2*E*,4*S*)-4-[(2*R*,5*S*)-2-(4-fluorobencil)-6-metil-5-(5-metil-1,2-isoxazol-3-carboxamido)-4-oxoheptanamido]-5-[(3*S*)-2-oxopirrolidin-3-il]pent-2-enoato de etilo

sorafenibum


sorafenib

4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-
N²-methylpyridine-2-carboxamide

sorafénib

4-[4-[[[4-chloro-3-(trifluorométhyl)phényl]carbamoyle]amino]phénoxy]-
N-méthylpyridine-2-carboxamide

sorafenib

4-(4-{3-[4-cloro-3-(trifluorometil)fenil]ureido}fenoxi)-
N²-metilpiridina-2-carboxamidaC₂₁H₁₆ClF₃N₄O₃**squalaminum**


squalamine

(24*R*)-3β-[3-(4-aminobutylamino)propylamino]-7α-hydroxy-
5α-cholestan-24-yl hydrogen sulfate

squalamine

hidrogénosulfate de (24*R*)-3β-[[3-[(4-aminobutyl)amino]=
propyl]amino]-7α-hidroxi-5α-cholestan-24-yle

escualamina

hidrógenosulfato de (24*RS*)-3β-[3-(4-aminobutilamino)propilamino]-
7α-hidroxi-5α-colestan-24-iloC₃₄H₆₅N₃O₅S**tacedinalinum**


tacedinaline

4-acetamido-*N*-(2-aminophenyl)benzamide

tacédinaline

4-(acétylamino)-*N*-(2-aminophényl)benzamide

tacedinalina

4-acetamido-*N*-(2-aminofenil)benzamidaC₁₅H₁₅N₃O₂

telbivudinum


telbivudine

1-(2-deoxy- β -L-*erythro*-pentofuranosyl)-5-methylpyrimidine-2,4(1*H*,3*H*)-dione

telbivudine

1-(2-désoxy- β -L-*érythro*-pentofuranosyl)-5-méthylpyrimidine-2,4(1*H*,3*H*)-dione

telbivudina

1-(2-desoxi- β -L-*eritro*-pentofuranosil)-5-metilpirimidina-2,4(1*H*,3*H*)-diona $C_{10}H_{14}N_2O_5$ **tolevamerum**

tolevamer


poly[1-(4-sulfophenyl)ethylene]

tolévamer

poly[1-(4-sulfophényl)éthylène]

tolevámero

poli[1-(4-sulfofenil)etileno]

 $(C_8H_8O_3S)_n$ 


**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Proposed International Nonproprietary Names (Prop. INN): List 88
Dénominations communes internationales proposées (DCI Prop.): Liste 88
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 88
(WHO Drug Information, Vol. 17, No. 1, 2003)

- | | | |
|-------|---|--|
| p. 58 | lurasidonum
lurasidone | <i>replace the chemical name by the following:</i>
(3aR,4S,7R,7aS)-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl]hexahydro-4,7-methano-2H-isindole-1,3-dione |
| p. 60 | delete/supprimer/suprimase | insert/insérer/insértase |
| | mitratapidum
mitratapid
mitratapid
mitratapid | mitratapidum
mitratapide
mitratapide
mitratapida |

Recommended International Nonproprietary Names (Rec. INN): List 49
Dénominations communes internationales recommandées (DCI Rec.): Liste 49
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 49
(WHO Drug Information, Vol. 17, No. 2, 2003)

- | | | |
|--------|---|---|
| p. 118 | axomadolum
axomadol
axomadol
axomadol | <i>replace the molecular formula by the following:</i>
<i>remplacer la formule brute par :</i>
<i>sustitúyase la fórmula molecular por:</i> |
|--------|---|---|



Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impairs des listes des DCIs proposées.

El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.

